Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2) | MicrobiomeTrials← Back to trialsNCT07726563
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-05-19Est. Completion: 2029-01-31
Enrollment target: 20 participants Locations- National Taiwan University Hospital, Taipei City, Taipei, Taiwan
Other microbiome trials you might be interested in
Spinal Cord InjuryAmyotrophic Lateral SclerosisBrain Stem InfarctionsLocked-in SyndromeMuscular Dystrophy
VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans an…
Providence, United StatesEst. completion Jun 30, 2027
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisImmune-Mediated Necrotizing Myopathy
Antisynthetase Syndrome
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participant…
Phoenix, United StatesCompleted Jul 2, 2026